Clinical Observation on the Efficacy of Patient-Donor Derived Probiotics in Improving Intestinal Flora Disorder in Patients With Intestinal Acute Graft-Versus-Host Disease (aGVHD)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Patient-Donor Derived Probiotics.
- Who it may be relevant to
- Registry conditions: Acute Graft-Versus-Host Disease. Basic parameters: from 50 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
To clinically evaluate the efficacy of patient- and/or donor-derived probiotics in ameliorating intestinal flora dysbiosis in patients with acute intestinal graft-versus-host disease (aGVHD), thereby mechanistically enhancing clinical outcomes and quality of life through intestinal microbiome modulation.
Detailed description
Study Design Overview:
Ten patients aged \>50 years scheduled for haploidentical hematopoietic stem cell transplantation (HSCT) will be enrolled. Stool specimens will be collected from both patients and donors (due to frequent depletion of beneficial bacteria in such patients, donor specimens are essential to enhance probiotic detection and cultivation rates). Patient specimens will undergo 16S rDNA intestinal microbiome analysis.
Upon clinical diagnosis of intestinal aGVHD:
1. Pre-collected patient and donor specimens will be homogenized 2. Target isolation and culture of core beneficial bacteria (Lactobacillus and Bifidobacterium) 3. Strain identification via TOF mass spectrometry 4. Fermentation and preparation of 200 enteric-coated capsules (100 Lactobacillus capsules + 100 Bifidobacterium capsules)
Post-intervention assessment (100 days after administration):
Changes in microbiome composition, relative abundance, species diversity, biochemical indicators, and bowel movement characteristics will be evaluated to assess the therapeutic efficacy of patient/donor-derived Lactobacillus and Bifidobacterium in GVHD.
Interventions
- Drug Patient-Donor Derived Probiotics
To clinically evaluate the efficacy of patient- and/or donor-derived probiotics in ameliorating intestinal flora dysbiosis in patients with acute intestinal graft-versus-host disease (aGVHD), thereby mechanistically enhancing clinical outcomes and quality of life through intestinal microbiome modulation.
Primary outcome measures
- Clinical response rate of intestinal acute graft-versus-host disease (aGVHD) [Time frame: within 100 days]
Secondary outcome measures (1)
- To study the changes of intestinal flora of subjects before and after taking probiotics from patients for 100 days [Time frame: within 100 days]
Eligibility criteria
Inclusion criteria
Subjects eligible for this study must satisfy all of the following criteria:
- Age >50 years, regardless of gender;
- Scheduled for haploidentical hematopoietic stem cell transplantation;
- ECOG performance status score ≤2;
- Voluntarily participate and provide written informed consent.
Exclusion criteria
Subjects presenting with any of the following conditions will be excluded from this study:
- Active or chronic infectious diseases, including recent febrile symptoms (axillary temperature ≥37.3°C within 48h);
- Gastrointestinal disorders:
- Clostridioides difficile infection (CDI): Recurrent or refractory CDI;
- Other conditions: Ulcerative colitis, Crohn's disease, irritable bowel syndrome (IBS), diarrhea associated with dysbiosis, liver cirrhosis;
- Allergic or immune-mediated diseases:
Autoimmune hepatitis, systemic lupus erythematosus (SLE), ankylosing spondylitis, immune-mediated osteoarthritis, allergic dermatitis, immune thrombocytopenic purpura (ITP);
- Antibiotic usage within 7 days prior to enrollment.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & P — Tianjin
Identifiers
NCT: NCT07188909 · IIT2025086